ValuEngine cut shares of Myokardia (NASDAQ:MYOK) from a hold rating to a sell rating in a research report released on Friday, December 1st.
Other equities research analysts have also recently issued reports about the stock. BMO Capital Markets restated a buy rating and set a $45.00 price objective (up from $32.00) on shares of Myokardia in a research note on Tuesday, August 8th. Zacks Investment Research upgraded shares of Myokardia from a sell rating to a hold rating in a research report on Tuesday, October 17th. TheStreet cut shares of Myokardia from a c rating to a d+ rating in a research report on Friday, November 3rd. Wedbush reiterated an outperform rating and issued a $51.00 price target on shares of Myokardia in a research report on Wednesday, September 20th. Finally, Credit Suisse Group reissued an outperform rating and issued a $55.00 price target (up previously from $45.00) on shares of Myokardia in a research note on Tuesday, September 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Myokardia currently has an average rating of Buy and a consensus target price of $55.00.
Myokardia (NASDAQ MYOK) opened at $39.25 on Friday. Myokardia has a 1-year low of $10.55 and a 1-year high of $49.55.
Myokardia (NASDAQ:MYOK) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.42). Myokardia had a negative return on equity of 14.92% and a negative net margin of 53.49%. The company had revenue of $5.63 million for the quarter, compared to analysts’ expectations of $6.10 million. During the same period last year, the business posted ($0.35) earnings per share. The firm’s quarterly revenue was up 58.6% compared to the same quarter last year. equities research analysts predict that Myokardia will post -1.62 earnings per share for the current fiscal year.
In related news, insider Anastasios Gianakakos sold 4,300 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $40.86, for a total value of $175,698.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kevin P. Starr sold 601,400 shares of the business’s stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $43.00, for a total value of $25,860,200.00. The disclosure for this sale can be found here. In the last three months, insiders sold 1,286,713 shares of company stock valued at $55,102,695. 33.40% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of MYOK. Vanguard Group Inc. lifted its holdings in shares of Myokardia by 8.9% during the first quarter. Vanguard Group Inc. now owns 686,119 shares of the biotechnology company’s stock worth $9,022,000 after buying an additional 55,927 shares during the last quarter. Hershey Trust Co. lifted its holdings in shares of Myokardia by 26.0% during the third quarter. Hershey Trust Co. now owns 20,064 shares of the biotechnology company’s stock worth $860,000 after buying an additional 4,145 shares during the last quarter. EAM Investors LLC acquired a new position in shares of Myokardia during the third quarter worth approximately $4,216,000. Fernwood Investment Management LLC lifted its holdings in shares of Myokardia by 409.1% during the third quarter. Fernwood Investment Management LLC now owns 246,382 shares of the biotechnology company’s stock worth $10,557,000 after buying an additional 197,989 shares during the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Myokardia by 25.7% during the second quarter. Swiss National Bank now owns 31,790 shares of the biotechnology company’s stock worth $416,000 after buying an additional 6,500 shares during the last quarter. Hedge funds and other institutional investors own 63.61% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Myokardia (NASDAQ:MYOK) Downgraded to “Sell” at ValuEngine” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://ledgergazette.com/2017/12/11/myokardia-myok-downgraded-by-valuengine.html.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Myokardia Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia Inc and related companies with MarketBeat.com's FREE daily email newsletter.